Co-infusion of donor adipose tissue-derived mesenchymal and hematopoietic stem cells helps safe minimization of immunosuppression in renal transplantation – single center experience

References

• Vanikar AV, Goplani KR, Feroz A, et al. Operational tolerance in living-related renal transplantation: A single-center experience. Transplant Proc. 2011;43(5):1551–1558
   PubMedGoogle Scholar
• Trivedi HL, Vanikar AV, Modi PR, et al. In pursuit of the ultimate: The initial Ahmedabad journey toward transplantation tolerance. Transplant Proc. 2007;39(3):653–657
   Google Scholar
• Vanikar AV, Trivedi HL, Feroz A, et al. Effect of co-transplantation of mesenchymal stem cells and hematopoietic stem cells as compared to hematopoietic stem cell transplantation alone in renal transplantation to achieve donor hypo-responsiveness. Int Urol Nephrol. 2011;43(1):225–232
   PubMed Web of Science ®Google Scholar
• Nakajima H, Leonard WJ. Impaired peripheral deletion of activated T cells in mice lacking the common cytokine receptor gamma chain. J Immunol. 1997;159:4737–4744
   Google Scholar
• Fangmann J, Dalchau AR, Fabre JW. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides. J Exp Med. 1992;175:1521–1529
   PubMed Web of Science ®Google Scholar
• Sherwood RA, Brent L, Rayfield LS. Presentation alloantigens by host cells. Eur J Immunol. 1986;16:569–574
   PubMedGoogle Scholar
• Auchincloss H Jr. In search of the elusive Holy Grail: The mechanisms and prospects for achieving clinical transplantation tolerance. Am J Transplant. 2001;1:6–12
   Google Scholar
• Shirwan H. Chronic allograft rejection: Do the Th 2 cells preferentially induced by indirect alloantigen recognition play a dominant role? Transplantation. 1999;68:715–726
   Google Scholar
• Vincenti F. Immunosuppression minimization: Current and future trends in transplant immunosuppression. J Am Soc Nephrol. 2003;14:1940–1948
   PubMed Web of Science ®Google Scholar
• Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation. 2001;71:1282–1287
   PubMed Web of Science ®Google Scholar
• Kreis H, Cisterne J-M, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation. 2000;69:1252–1260
   PubMed Web of Science ®Google Scholar
• Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil — A prospective randomized study. Steroid Withdrawal Study Group. Transplantation. 1999;68:1865–1874
   PubMed Web of Science ®Google Scholar
• Vanrenterghem Y, Lebranchu Y, Hene R, et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation. 2000;70:1352–1359
   PubMed Web of Science ®Google Scholar
• Squifflet J-P, Vanrenterghem Y, van Hooff JP, et al. Safe withdrawal of corticosteroids or mycophenolate mofetil: Results of a large, prospective, multicenter, randomized study. Transplant Proc. 2002;34:1584–1586
   Google Scholar
• Salvatierra O, Melzer J, Potter D, et al. A seven-year experience with donor-specific blood transfusions. Results and considerations for maximum efficacy. Transplantation. 1985;40:654–659
   Google Scholar
• Terasaki PI. The beneficial transfusion effect on kidney graft survival attributed to clonal deletion. Transplantation. 1984;37:119–125
   PubMed Web of Science ®Google Scholar
• Kirk AD, Mannon RB, Swanson SJ, Hale DA. Strategies for minimizing immunosuppression in kidney transplantation. Transplant Int. 2005;18:2–14
   PubMedGoogle Scholar
• Ricordi C, Karatzas T, Nery J, et al. High-dose bone marrow infusions to enhance allograft survival. The effect of timing. Transplantation. 1997;63(1):7–11
   Google Scholar
• Ciancio G, Miller J, Garcia-Morales RO, et al. Six-year clinical effect of donor bone marrow infusions in renal transplant patients. Transplantation. 2001;71:827–835
   PubMed Web of Science ®Google Scholar
• Buhler LH, Spitzer TR, Sykes M, et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation. 2002;74:1405–1409
   PubMed Web of Science ®Google Scholar
• Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation. 2002;73:1386–1391
   PubMed Web of Science ®Google Scholar
• Hutchinson JA, Brem-Exner BG, Riquelme P, et al. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transplant Int. 2008;21:742–754
   PubMedGoogle Scholar
• Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants – A randomized controlled trial. J Am Med Assoc. 2012;307(11):1169–1177
   PubMed Web of Science ®Google Scholar
• Kirk AD, Mannon RB, Kleiner DE, et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation. 2005;80:1051–1059
   PubMed Web of Science ®Google Scholar
• Szczech LA, Berlin JA, Feldman HI. Anti-lymphocyte antibody induction therapy study group. The effect of anti-lymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Ann Intern Med. 1998;128:817–826
   PubMed Web of Science ®Google Scholar
• Peddi VR, Bryant M, Roy-Chaudhury P, et al. Safety, efficacy, and cost analysis of Thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation. 2002;73:1514–1518
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause specific mortality in renal transplant recipients. J Am Soc Nephrol. 2002;13:769–772
   PubMedGoogle Scholar
• Jae Woo Jung, Minsuk Kwon, Jae Chol Choi, et al. Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei Med J. 2013;54(5):1293–1296
   Google Scholar
• Ikehara S. New strategies for allogeneic bone marrow transplantation and organ allografts. Acta Hematol. 1999;101:68–77
   Google Scholar
• Gorczynski RM, Chen Z, Kai Y, Lei J. Evidence for persistent expression of OX2 as a necessary component of prolonged renal allograft survival following portal vein immunization. Clin Immunol. 2000;97(1):69–78
   Google Scholar
• Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838–3843
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57:11–20
   PubMed Web of Science ®Google Scholar
• Tse WT, Pendleton JD, Beyer WM, et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation. 2003;75:389–397
   PubMed Web of Science ®Google Scholar
• Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30:42–48
   PubMed Web of Science ®Google Scholar
• Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003;101:3722–3729
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57:11–20
   PubMed Web of Science ®Google Scholar
• Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003;101:3722–3729
   PubMed Web of Science ®Google Scholar
• Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B- cell functions. Blood. 2006;107:367–372
   PubMed Web of Science ®Google Scholar
• Ivanova-Todorova E, Bochev I, Mourdjeva M, et al. Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett. 2009;126:37–42
   PubMed Web of Science ®Google Scholar
• Ge W, Jiang J, Arp J, et al. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation. 2010;90:1312–1320
   PubMedGoogle Scholar
• Calne RY, Friend PJ, Moffatt S, et al. Prope tolerance, perioperative Campath 1H, and low dose cyclosporine monotherapy in renal allograft recipients (letter). Lancet. 1998;351:1701–1702
   PubMed Web of Science ®Google Scholar